BIODOL THERAPEUTICS
Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (Cyril Rivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.
BIODOL THERAPEUTICS
Social Links:
Industry:
Therapeutics
Founded:
2015-01-01
Address:
Clapiers, Languedoc-Roussillon, France
Country:
France
Website Url:
http://www.biodol.eu
Total Employee:
1+
Status:
Active
Total Funding:
4.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Font Awesome Apache Euro OVH OVH DNS OVH Mail
Similar Organizations
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Advisors List
Current Employees Featured
Founder
Investors List
V-Bio Ventures
V-Bio Ventures investment in Series A - Biodol Therapeutics
Official Site Inspections
http://www.biodol.eu
- Host name: cluster011.ovh.net
- IP address: 213.186.33.40
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Biodol Therapeutics"
Biodol Therapeutics
Biodol Therapeutics made a breakthrough discovery on the origin and maintenance of NP. Biodol Therapeutics specifically demonstrated that FLT3 is necessary and sufficient to generate … See details»
Biodol Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Biodol Therapeutics. Use the PitchBook Platform to explore the full profile. See details»
Biodol Therapeutics - Crunchbase Company Profile & Funding
Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) … See details»
BIODOL THERAPEUTICS Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for BIODOL THERAPEUTICS of MONTARNAUD, OCCITANIE. Get the latest business insights from Dun … See details»
Biodol - VentureRadar
Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) … See details»
Biodol Therapeutics | F6S
BIODOL Therapeutics is a biotech company developing first-in-class compounds for treating chronic pain. It is based on the discovery by Biodol's scientists of the target FLT3, which is a … See details»
Biodol - BIO International Convention 2025
BIODOL THERAPEUTICS is a clinical-stage company developing first-in-class compounds for pain management with a novel mechanism of action that targets a key step in the … See details»
Biodol Therapeutics from France raises €7M to advance Chronic …
May 27, 2024 Biodol Therapeutics, a biotech firm based in Montarnaud, France, has secured €7 million in funding from BPI France through the i-DEMO call for projects. This funding will … See details»
Biodol - VentureRadar
"Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) … See details»
Biodol Therapeutics gathers €7 million to progress its oral,
With the parallel support of the venture capital fund V-Bio Ventures, Biodol Therapeutics will lead a consortium also composed of 2 academic partners (Institute for Neurosciences of … See details»
BIODOL THERAPEUTICS – Funding, Valuation, Investors, News
BIODOL Therapeutics is a biotech company developing first-in-class compounds for treating chronic pain. It is based on the discovery by Biodol's scientists of the target FLT3, which is a … See details»
A novel approach to neurology could bring relief to people in pain
Aug 31, 2020 This month, V-Bio Ventures announced their investment in Biodol Therapeutics, a French start-up looking to make a difference to people suffering from chronic pain. The … See details»
Biodol Therapeutics – Quest for Health
Biodol Therapeutics, fondée en 2015, développe des composés innovants de première classe pour le traitement de la douleur chronique (DC). Biodol Therapeutics a identifié la kinase à … See details»
KYORIN and BIODOL Enter Into Option Agreement for Novel Pain …
About BIODOL Therapteutics BIODOL Therapeutics (www.biodol.eu), founded in 2015, specializes in developing first-in-class compounds for pain treatment. The company has … See details»
V-Bio Ventures Portfolio company Biodol Therapeutics Reports on …
May 26, 2025 Biodol Therapeutics (www.biodol.eu), founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the … See details»
Biodol Therapeutics announces the nomination of its first …
About Biodol Therapeutics Biodol Therapeutics (www.biodol.eu), founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified … See details»
Microsoft Word - 200831 Biodol Therapeutics Series A final_V2
Biodol Therapeutics receives €4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol … See details»
BIODOL Therapeutics and KYORIN Pharmaceutical announce …
Biodol Therapeutics (www.biodol.eu), founded in 2015, specializes in developing first-in-class compounds for pain treatment. The company has identified the Receptor Tyrosine Kinase … See details»
BIODOL Therapeutics Reports on Ongoing Phase 1 Clinical Study …
Biodol Therapeutics (www.biodol.eu), founded in 2015, specializes in developing first-in-class compounds for pain treatment. The company has identified the Receptor Tyrosine Kinase … See details»
EU and Germany push for a new World Trade Organization
1 day ago Brussels and Berlin have launched a new initiative aimed at bypassing the long-standing paralysis of the World Trade Organization, as caused by the United States. But how … See details»